Request Trial
shutterstock_1595586766_ken_wolter
Ken Wolter / Shutterstock.com
6 March 2020PharmaClaire Irvine

Broad Institute down (but not out) in the European fight over CRISPR IP

Following the upholding in January 2020 of the revocation of the Broad Institute’s lead European patent (EP 2771468) by a European Patent Office (EPO) Appeal Board, there has been speculation that the University of California and its co-applicants (UC) have the upper hand in the European fight over the IP of clustered regularly interspaced short palindromic repeats (more commonly known as ‘CRISPR’), the latest incarnation of genome editing and deliberate alteration.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Teva and Aurinia settle generics dispute over lupus drug, voclosporin
21 August 2026   Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.
Pharma
SK Biopharmaceuticals settles epilepsy generic dispute
20 August 2026   A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.
Pharma
Vanda revives challenge over braille-free label on generic sleep disorder drug
19 August 2026   Questions over braille on a generic sleep disorder drug label will face fresh scrutiny after an appeals court found fault with the FDA’s approach.


Editor's picks

Abbott fends off Chinese rival’s patent challenge at UPC
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026

Editor's picks

MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026

More features

Teva and Aurinia settle generics dispute over lupus drug, voclosporin
SK Biopharmaceuticals settles epilepsy generic dispute
Vanda revives challenge over braille-free label on generic sleep disorder drug
Europe’s missing biotech bridge: Why IP ownership matters more than capital access
Novartis scores UK win in high-stakes Entresto fight
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
Lilly mounts defence as generics circle Mounjaro and Zepbound
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany